For Healthcare Professionals Only.
Journal: JAMA Dermatology
Validity Period (for CME): July 2026
(click to expand) Information for Doctor CME Category 3A (Self-study)
CME points will be awarded to doctors who submit claims for reading papers from Refereed Journals recommended by SMC or listed in PubMed. Papers must be published within the last 2 years. Claims from other publications, such as newsletters, magazines or non-refereed journals, will be rejected. This article serves as a concise overview of the key insights extracted from the original article. Hence, ensure to cite the actual research paper in your CME Cat. 3A claim. Link to the paper is provided in the footnotes. For more information, visit: [Criteria], [List]
(click to expand) Information for Pharmacist CPE Category 3A (Reading)
CPE points will be award to pharmacists who submit claims for reading papers from the list of journals recommended by the SPC if they wish to minimise the rejection of claims for reading non-recognised materials. This article serves as a concise overview of the key insights extracted from the original article. Hence, ensure to cite the actual research paper in your CPE Cat. 3A claim. Link to the paper is provided in the footnotes. For more information, visit: [Main], [Guide, Page 26], [List]
Overview of Systemic Treatments for Atopic Dermatitis
- Historical Context: Multiple systemic treatments for atopic dermatitis (AD) have been approved since 2017. However, most of these drugs, including lebrikizumab, have not been compared in head-to-head trials.
- Objective of the Study: This study aims to compare the efficacy and safety of systemic immunomodulatory treatments for AD, including lebrikizumab, using a living systematic review and network meta-analysis. This comparison is essential as direct head-to-head trials are limited.
- About Lebrikizumab: A monoclonal antibody targeting interleukin-13, approved by the European Medicines Agency in November 2023 for the treatment of moderate to severe atopic dermatitis, and is under review in other regions. It was previously evaluated only in placebo-controlled trials.
Login to read more
